Trial Profile
A Multi-centre, Randomised, Double-blinded, Controlled, Dose-escalation Trial on Safety and Efficacy of Activated Recombinant FVII Analogue (NN1731) in the Treatment of Joint Bleeds in Congenital Haemophilia Patients With Inhibitors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Vatreptacog alfa (Primary) ; Eptacog alfa
- Indications Congenital disorders; Haemophilia
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 19 May 2014 New trial record